How health-system pharmacy actually evaluates a new oncology drug

There is a version of this process that lives on a slide: submission, review, committee, decision. The real version has more steps, more people, and a different center of gravity. The clinical question is usually settled early. What takes time is everything downstream of it.

Here is the sequence as it actually runs inside most health systems, and the questions that decide the outcome at each stage.

1. Someone has to ask for it

Nothing enters formulary review on its own. A physician, a pharmacy specialist, or a service line leader submits a request, and the quality of that submission shapes everything after it. A request that arrives without a defined place in therapy, without a named population, and without a sponsor who will answer questions in committee is a request that gets deferred.

The first filter is not evidence. It is ownership. Who wants this, for which patients, and who is accountable for using it the way the request describes.

2. Pharmacy builds the evidence picture

A drug information pharmacist or an oncology clinical specialist assembles the review. The pivotal trial matters, but the questions asked of it are narrower than the trial design suggests:

• What is the comparator, and is it what we actually use here?
• Does the trial population match the patients in our clinic, including the ones with the comorbidities that would have excluded them from enrollment?
• What is the effect size in terms the committee can weigh: months, response, toxicity avoided?
• What is the monitoring burden, and who absorbs it?
• Where does this sit relative to the regimens already on formulary?

This is where a well-built dossier earns its keep and a poorly built one gets set aside. The packages that land are the ones organized around place in therapy rather than around the trial. The ones that stall are the ones that answer a question the committee did not ask.

3. The operational review runs in parallel

This is the stage most external submissions underestimate. Before a committee can say yes, someone has to answer whether the system can actually deliver the drug.

• Acquisition. Is it available through our wholesaler, or is it limited distribution? Is it 340B eligible at the sites where it will be used?
• Preparation. Does it need a specific compounding environment, a hazardous handling designation, or dedicated equipment?
• Administration. How long is the chair time? Does the first dose require extended observation? What does that do to infusion capacity?
• Billing. Is there a product-specific code yet, or does it bill unclassified? Medical benefit or pharmacy benefit? What does the payer mix look like for this population? And somewhere in this meeting, pharmacy IT will explain that the real holdup is that the drug is not in Multum yet. Everyone will nod like this is news. It happens every time.
• Build. Order sets, regimen library, pump library, and pathway entries all have to change, and that work sits in a queue behind everything else.

A clinically compelling agent with an unresolved billing pathway and a four-hour chair time is not a fast yes. It is a yes with conditions, and for a while it is also a possible no. Call it Schrödinger's formulary status: nobody actually knows which one it is until the vote closes.

4. Finance asks a different question

The committee is weighing benefit. Finance is weighing exposure. Those are not the same conversation, and a submission that only addresses the first one leaves the second to be improvised.

The financial review asks what the annualized institutional cost looks like at expected volume, what reimbursement is realistic by payer, whether there is a gap between acquisition cost and expected payment, and what happens to that gap if utilization runs above forecast. In oncology, where a single regimen can move a service line's margin, this review is not a formality.

5. The vote almost never lands as a clean yes or no

More often it is yes with conditions, yes for now, or no for reasons that have nothing to do with the drug itself. The common shapes:

1. Add with criteria for use. Approved for a defined population, with documentation requirements and a monitoring plan.
2. Add restricted. Approved but limited to a specialty, a site, or a protocol.
3. Defer pending information. Usually an operational or financial gap, not a clinical one.
4. Non-formulary with exception pathway. Available case by case, which in practice means available slowly.
5. Decline. Least common, and usually because an existing option covers the same place in therapy.

6. The decision has to survive implementation

A formulary approval that never reaches the order set does not change practice. After the vote there is build work, pathway alignment, staff communication, and a utilization review some months later to see whether the drug is being used the way the criteria described. That last step gets skipped more often than anyone admits. Skip it a few cycles in a row and the criteria for use stop meaning anything, because nobody is actually checking.

What this means if you are on the outside

For anyone preparing evidence for a health-system audience, the practical implications are straightforward:

• Lead with place in therapy against the comparator the institution actually uses.
• Answer the operational questions before they are asked: handling, chair time, coding, and distribution.
• Be specific about the population, including who this is not for.
• Expect the financial question, and expect it to be asked by someone who is not a clinician.
• Understand that the committee calendar is real. A class review that happens in March does not happen again in April because a submission arrived late.

None of this is about persuasion. Health-system pharmacy committees are structured to be skeptical on purpose, and the ones that work are the ones where the skepticism is applied evenly. The submissions that move are the ones that make the committee's job easier rather than the ones that make the strongest case.

Robert Walters, PharmD, MBA is the founder of Walters Rx Strategy and is Apexus Advanced 340B Certified. He spent fifteen years leading health-system pharmacy operations across acute care, a cancer center, infusion, and emergency department pharmacy. Book a consult or read more insights.

This article is general and informational. It is not legal, regulatory, clinical, or medical advice, and it does not recommend or promote any specific product or therapy.